Market Cap 8.07M
Revenue (ttm) 230,000.00
Net Income (ttm) -166.52M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -72,400.00%
Debt to Equity Ratio 0.00
Volume 57,200
Avg Vol 1,456,108
Day's Range N/A - N/A
Shares Out 5.56M
Stochastic %K 24%
Beta 1.46
Analysts Strong Buy
Price Target $6.00

Company Profile

Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It...

Industry: Biotechnology
Sector: Healthcare
Phone: 267 759 3680
Fax: 267 759 3681
Address:
12 Penns Trail, Newtown, United States
Twitties00
Twitties00 Jul. 5 at 10:56 AM
$TRAW $TRAW Best Healthcare funds on earth entered in December at $8.80. TWO antivirals may be worth BILLIONS. CEO was head of merger/acquisition for Merck. CMO is former CDC Director Redfield. BIRD FLU drug has shown TREMENDOUS EFFICACY. Potential market for the two antivirals is BILLIONS🐓🦠🔥
0 · Reply
Twitties00
Twitties00 Jul. 5 at 12:07 AM
$TRAW Scam! 😂
0 · Reply
Twitties00
Twitties00 Jul. 3 at 5:22 PM
$TRAW Nuff said…🚀🔥
0 · Reply
StellaJean
StellaJean Jul. 3 at 1:49 PM
$TRAW My yearly penance to remind folks that this is absolute scam company. Before it was TRAW it was ONTX a failed phase 3 company. They change names every few years so folks forget their past scams. If you want to pump and dump it have it but, never ever believe anyone that tells you they have something in their pipeline. Chances are they have absolutely no clue what they are talking about.
3 · Reply
janon10
janon10 Jun. 30 at 9:34 PM
$TRAW animal rule is a fact, but thats just my opinion , its a matter of when, and we will be rewarded . maybe could be weeks, maybe few months. But its necessary for global healthy. Eventually it will come. Redfield know how this things get done.
1 · Reply
Schube1255
Schube1255 Jun. 30 at 1:03 PM
0 · Reply
JohnSmith1212
JohnSmith1212 Jun. 30 at 12:23 PM
0 · Reply
Twitties00
Twitties00 Jun. 30 at 11:31 AM
$TRAW Traws is going head to head with Xofluza for seasonal influenza and going up against Bird Flu in Southeast Asia. The market for flu antivirals is BILLIONS. The potential for stockpiling is BILLIONS. The potential in a pandemic is BILLIONS. Thank you for your attention to this matter. 🇺🇸🐓🦠💸⏳💎
0 · Reply
DonCorleone77
DonCorleone77 Jun. 30 at 10:39 AM
$TRAW Traws Pharma announced multiple regulatory submissions Traws Pharma announced multiple regulatory submissions related to its antiviral pipeline. A proposed Phase 2 dose-ranging, non-inferiority study will evaluate the effects of tivoxavir marboxil, a potential best in class CAP-dependent endonuclease inhibitor, compared to XOFLUZA, in patients infected with seasonal influenza. A separate single arm will evaluate the effects of TXM in patients infected with H5N1 bird flu. The proposed study has been submitted for Human Research Ethics Committee review and is expected to enroll subjects in Australia and selected countries in Southeast Asia with high rates of human bird flu infections. Also, as a follow up to recent Pre-IND FDA interactions on TXM, Traws submitted briefing materials for a Type D meeting to enable further FDA dialog on a potential path to accelerated approval for bird flu. A proposed Phase 2 non-inferiority study will evaluate the effects of ratutrelvir, a potential best in class protease inhibitor that does not require ritonavir co-administration, compared to PAXLOVID, in newly diagnosed COVID patients. The proposed study that has been submitted for HREC review is intended to enroll patients on a 10-day treatment regimen for ratutrelvir compared to the approved 5-day regimen for PAXLOVID. In addition to efficacy and safety endpoints, the proposed study will also evaluate the rates of disease rebound as well as the incidence of Long COVID. A separate single arm will evaluate the safety and efficacy of ratutrelvir in newly diagnosed COVID patients who are ineligible for treatment with PAXLOVID.
0 · Reply
HoldnLoad
HoldnLoad Jun. 28 at 12:37 PM
$TRAW wish i held.
1 · Reply
Latest News on TRAW
Traws Pharma, Inc. (TRAW) Virtual Investor Event Transcript

Apr 1, 2025, 8:50 PM EDT - 3 months ago

Traws Pharma, Inc. (TRAW) Virtual Investor Event Transcript


Traws Pharma Announces Management Updates

Mar 28, 2025, 4:30 PM EDT - 3 months ago

Traws Pharma Announces Management Updates


Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule

Feb 28, 2025, 7:00 AM EST - 4 months ago

Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule


Traws Pharma stock soars 200% on encouraging bird flu drug data

Dec 23, 2024, 12:00 PM EST - 6 months ago

Traws Pharma stock soars 200% on encouraging bird flu drug data


Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors

Sep 20, 2024, 7:30 AM EDT - 10 months ago

Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors


Traws Pharma, Inc. Announces Special Shareholders Meeting Results

Sep 17, 2024, 4:05 PM EDT - 10 months ago

Traws Pharma, Inc. Announces Special Shareholders Meeting Results


Traws Pharma, Inc. (TRAW) Corporate Update Call Transcript

Aug 20, 2024, 9:02 AM EDT - 11 months ago

Traws Pharma, Inc. (TRAW) Corporate Update Call Transcript


Traws Pharma Announces New Employee Inducement Grants

Apr 2, 2024, 7:15 AM EDT - 1 year ago

Traws Pharma Announces New Employee Inducement Grants


Onconova Expands Leadership Team with Two Key Appointments

Oct 24, 2023, 8:00 AM EDT - 1 year ago

Onconova Expands Leadership Team with Two Key Appointments


Twitties00
Twitties00 Jul. 5 at 10:56 AM
$TRAW $TRAW Best Healthcare funds on earth entered in December at $8.80. TWO antivirals may be worth BILLIONS. CEO was head of merger/acquisition for Merck. CMO is former CDC Director Redfield. BIRD FLU drug has shown TREMENDOUS EFFICACY. Potential market for the two antivirals is BILLIONS🐓🦠🔥
0 · Reply
Twitties00
Twitties00 Jul. 5 at 12:07 AM
$TRAW Scam! 😂
0 · Reply
Twitties00
Twitties00 Jul. 3 at 5:22 PM
$TRAW Nuff said…🚀🔥
0 · Reply
StellaJean
StellaJean Jul. 3 at 1:49 PM
$TRAW My yearly penance to remind folks that this is absolute scam company. Before it was TRAW it was ONTX a failed phase 3 company. They change names every few years so folks forget their past scams. If you want to pump and dump it have it but, never ever believe anyone that tells you they have something in their pipeline. Chances are they have absolutely no clue what they are talking about.
3 · Reply
janon10
janon10 Jun. 30 at 9:34 PM
$TRAW animal rule is a fact, but thats just my opinion , its a matter of when, and we will be rewarded . maybe could be weeks, maybe few months. But its necessary for global healthy. Eventually it will come. Redfield know how this things get done.
1 · Reply
Schube1255
Schube1255 Jun. 30 at 1:03 PM
0 · Reply
JohnSmith1212
JohnSmith1212 Jun. 30 at 12:23 PM
0 · Reply
Twitties00
Twitties00 Jun. 30 at 11:31 AM
$TRAW Traws is going head to head with Xofluza for seasonal influenza and going up against Bird Flu in Southeast Asia. The market for flu antivirals is BILLIONS. The potential for stockpiling is BILLIONS. The potential in a pandemic is BILLIONS. Thank you for your attention to this matter. 🇺🇸🐓🦠💸⏳💎
0 · Reply
DonCorleone77
DonCorleone77 Jun. 30 at 10:39 AM
$TRAW Traws Pharma announced multiple regulatory submissions Traws Pharma announced multiple regulatory submissions related to its antiviral pipeline. A proposed Phase 2 dose-ranging, non-inferiority study will evaluate the effects of tivoxavir marboxil, a potential best in class CAP-dependent endonuclease inhibitor, compared to XOFLUZA, in patients infected with seasonal influenza. A separate single arm will evaluate the effects of TXM in patients infected with H5N1 bird flu. The proposed study has been submitted for Human Research Ethics Committee review and is expected to enroll subjects in Australia and selected countries in Southeast Asia with high rates of human bird flu infections. Also, as a follow up to recent Pre-IND FDA interactions on TXM, Traws submitted briefing materials for a Type D meeting to enable further FDA dialog on a potential path to accelerated approval for bird flu. A proposed Phase 2 non-inferiority study will evaluate the effects of ratutrelvir, a potential best in class protease inhibitor that does not require ritonavir co-administration, compared to PAXLOVID, in newly diagnosed COVID patients. The proposed study that has been submitted for HREC review is intended to enroll patients on a 10-day treatment regimen for ratutrelvir compared to the approved 5-day regimen for PAXLOVID. In addition to efficacy and safety endpoints, the proposed study will also evaluate the rates of disease rebound as well as the incidence of Long COVID. A separate single arm will evaluate the safety and efficacy of ratutrelvir in newly diagnosed COVID patients who are ineligible for treatment with PAXLOVID.
0 · Reply
HoldnLoad
HoldnLoad Jun. 28 at 12:37 PM
$TRAW wish i held.
1 · Reply
Thevisitors
Thevisitors Jun. 28 at 3:12 AM
$TRAW big red monday.
1 · Reply
Brence04
Brence04 Jun. 27 at 1:33 PM
$TRAW I’m out took the L goodluck holding
1 · Reply
janon10
janon10 Jun. 27 at 9:30 AM
$TRAW Price went from 1,29 overnight with low vol, to 1,43 again, our current support level (1.40-1,43). Classical bear trap. Weak hands out. Short interest were increased on 25 June by 500%. Fundamentals didnt change . If they want to short this more, ill be prepared to add, and they will must be prepared to close them. This semester will be epic. News about Tivoxavir, Ratrutelvir, Rigosertib o Narazaciclib are coming. This is just my opinion, good luck to all!!
0 · Reply
sthm
sthm Jun. 27 at 6:18 AM
$TRAW 1.29 overnight...
1 · Reply
janon10
janon10 Jun. 26 at 9:23 PM
$TRAW Cambodia reports fifth human H5N1 Bird Flu case in 2025 in a 65-year-old woman WITHOUT poultry exposure. She is currently treated in ICU on organ support. All previous cases in Cambodia (6) this year have died. They were treated with Tamiflu. Its imperative to have new antivirals that are efective vs agresive strains. Tivoxavir is the solution, it is vey effective for all kinds of strains. Animal rule + stockpilling will likely come.
0 · Reply
Brence04
Brence04 Jun. 26 at 5:10 PM
$TRAW big buys someone knows something
0 · Reply
Twitties00
Twitties00 Jun. 26 at 3:30 PM
$TRAW bunch of no names…😂🐓🦠🇺🇸💸💎🚀⏳🔥
0 · Reply
DaBullhead
DaBullhead Jun. 26 at 2:58 PM
$TRAW You guys need to pump this one harder. It’s true value is starting to slow through. It’s setting up nicely for the next reverse split next May!
1 · Reply
JohnSmith1212
JohnSmith1212 Jun. 26 at 2:43 PM
0 · Reply
janon10
janon10 Jun. 25 at 3:03 PM
$TRAW wtf is happening here?
0 · Reply
sthm
sthm Jun. 25 at 11:20 AM
$TRAW Waiting patiently...
0 · Reply
janon10
janon10 Jun. 24 at 9:00 PM
$TRAW Can anyone imagine how much a drug could be worth if a single dose provided 21 days of protection against seasonal flu and its resistant variants, avian flu and its aggressive strains, human smallpox, and monkeypox? Can you picture anything capable of competing with this drug in terms of stockpiling for the military, healthcare workers, and the general population? I've already done my calculations.
1 · Reply